LATEST
外 Waitan Ludi Policy Terminal China industrial-policy monitor · updated 2026-10-25

Programme evidence / 坪山

Medical-device registration rewards — Pingshan

Registration-linked financial rewards, distinct from the registration decision itself.

1Reviewed documents
0Reviewed recipient observations
0Recipient observations to review

Window: 2020–2026; earlier legal bases can be included as context. Reviewed source labels confirm programme association and document stage. They do not confirm current legal force or payment. Allocation, eligibility and payment are separate meanings; no cross-instrument monetary total is calculated.

Policy basis · Searched; unresolvedImplementing rules · Reviewed evidenceApplications · Searched; unresolvedProposed recipients · Searched; unresolvedFinal allocations · Searched; unresolvedSettlement / recovery · Searched; unresolvedEvaluation / renewal · Searched; unresolved
Coverage by explicitly assigned round year

Blank years are not evidence that a programme did not operate. Cross-year rules and notices without an established round year appear below.

RoundPolicy basisImplementing rulesApplicationsProposed recipientsFinal allocationsSettlement / recoveryEvaluation / renewal
2026———————
2025———————
2024———————
2023———————
2022———————
2021———————
2020—1 reviewed—————

Eligibility and support terms

Source-specific rules; historical versions and exceptions may differ. These are not an automated eligibility decision.

Support rate / cap · Historical registration support; partial indexed text
(九)对新取得第三类、第二类医疗器械注册证且在我区产业化(取得生产批件或产生营收)的企业,按实际投入费用(包含医疗器械注册费、生物学评价费、临床试验费)的40%给予资助,第三类、第二类医疗器械产品分别最高不超过100万元/张、30万元/张。符合上述条件并通过国家创新医疗器械特别审查程序新取得第三类医疗器械注册证的,额外给予100万元/张的奖励。同一企业年度获得本项奖励总额最高500万元。 本措施责任部门为坪山区科技创新局,本实施细则由其负责解释,自发布之日起施行,2020年有效。
Original source →

Policy basis

No evidence linked for this stage. See the search audit below; absence has not been established.

Implementing rules

深圳市坪山区关于加快科技创新发展的若干措施实施细则
Partial indexed text · 2020-07-14 · 深圳市坪山区科技创新局 · round 2020 · Reviewed source
(九)对新取得第三类、第二类医疗器械注册证且在我区产业化(取得生产批件或产生营收)的企业,按实际投入费用(包含医疗器械注册费、生物学评价费、临床试验费)的40%给予资助,第三类、第二类医疗器械产品分别最高不超过100万元/张、30万元/张。符合上述条件并通过国家创新医疗器械特别审查程序新取得第三类医疗器械注册证的,额外给予100万元/张的奖励。同一企业年度获得本项奖励总额最高500万元。 本措施责任部门为坪山区科技创新局,本实施细则由其负责解释,自发布之日起施行,2020年有效。

Partial indexed source. Association reviewed; original bytes and current legal force not verified.

Original source ↗

Applications

No evidence linked for this stage. See the search audit below; absence has not been established.

Proposed recipients

No evidence linked for this stage. See the search audit below; absence has not been established.

Final allocations

No evidence linked for this stage. See the search audit below; absence has not been established.

Settlement / recovery

No evidence linked for this stage. See the search audit below; absence has not been established.

Evaluation / renewal

No evidence linked for this stage. See the search audit below; absence has not been established.

Recipients and projects

Amounts retain their source meaning and unit. Proposed support and allocations are not confirmed payments. Candidate rows require source review.

Download reviewed CSV Include candidates in CSV

Recipient / projectRound / supported periodAmountMeaningEvidence
No recipient observations linked yet.

Search audit

A completed search records an attempt, not proof of completeness or non-publication. Search results are discovery leads, not citations.

Citation-rooted topic view →